文献速递角膜与眼表疾病

头孢地尔联合PolyTrim治疗耐多药铜绿假单胞菌角膜炎兔模型疗效增强

Enhanced Efficacy of Cefiderocol With PolyTrim Combination Therapy in a Rabbit Model of Extensively Drug-Resistant Pseudomonas aeruginosa Keratitis.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2026-01-01

该研究在耐多药铜绿假单胞菌角膜炎兔模型中比较头孢地尔联合莫西沙星或PolyTrim的疗效。结果显示头孢地尔联合PolyTrim降低细菌负荷约6.9 log10 CFU并实现10/12角膜灭菌,优于单药及联合莫西沙星,且无前房侵犯和角膜穿孔。

要点

  • 头孢地尔联合PolyTrim在兔模型中实现近6.9 log10 CFU降低和10/12角膜灭菌。
  • PolyTrim单药降低细菌负荷3.2 log10 CFU,效果显著。
  • 含头孢地尔方案均未出现前房侵犯,所有头孢地尔和PolyTrim治疗组无角膜穿孔。

核心结论

  • 头孢地尔联合PolyTrim优于单药治疗及头孢地尔联合莫西沙星,可实现频繁灭菌并防止眼内播散和角膜穿孔。
  • 数据支持PolyTrim单用或联合头孢地尔作为耐多药铜绿假单胞菌角膜炎的有前景治疗候选。

研究设计与样本

  • 新西兰白兔角膜基质内注射5000 CFU铜绿假单胞菌株CDC1270,16小时后建立感染。
  • 感染眼每30分钟治疗一次,持续8小时,头孢地尔后5分钟给予莫西沙星或PolyTrim,另设单药和生理盐水组。

主要发现

  • 头孢地尔联合莫西沙星降低细菌负荷2.8 log10 CFU,优于各自单药,但无眼灭菌。
  • PolyTrim单药降低细菌负荷3.2 log10 CFU。
  • 头孢地尔联合PolyTrim降低细菌负荷近6.9 log10 CFU,12眼中10眼灭菌。
  • 生理盐水和莫西沙星组出现前房侵犯,含头孢地尔组均无前房侵犯。
  • 所有头孢地尔和PolyTrim治疗组无角膜穿孔。

关键数值与推荐

  • 细菌负荷以CFU/角膜计,前房培养和眼部炎症为评估指标。
  • 头孢地尔联合PolyTrim实现近6.9 log10 CFU降低和10/12角膜灭菌。

临床怎么用

  • 对于耐多药铜绿假单胞菌角膜炎,PolyTrim单用或联合头孢地尔可能是有前景的治疗选择。
  • 联合头孢地尔可防止前房侵犯和角膜穿孔。

局限性

  • 研究为兔模型,结果需临床验证。
  • 样本量未在摘要中报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The 2023 Pseudomonas aeruginosa keratitis outbreak linked to contaminated artificial tears underscored the need for new therapies against extensively drug-resistant ocular pathogens. In vitro data suggested additive or synergistic activity between the siderophore-cephalosporin cefiderocol (FDC) and either moxifloxacin (MOX) or polymyxin B sulfate (PB). Here, we tested whether combining FDC with the commercial formulations of MOX (0.5%) or PolyTrim (PT; PB 10,000 U/mL + trimethoprim 0.1%) improved in vivo outcomes. METHODS: New Zealand White rabbits were injected intrastromally with 5000 CFU of Pseudomonas aeruginosa strain CDC1270. After 16 hours, established infections were treated every 30 minutes for 8 hours with FDC, followed 5 minutes later by MOX or PT. Additional groups received monotherapies or saline. Bacterial burden (CFU/cornea) and anterior chamber cultures were determined, and ocular inflammation was assessed. RESULTS: FDC + MOX reduced bacterial burden by 2.8 log10 CFU, outperforming FDC and MOX monotherapies, although no eyes were sterilized. PT monotherapy produced a significant 3.2 log10 reduction in CFU. The FDC + PT combination yielded the most potent activity, with almost 6.9 log10 reduction and sterilization of 10 of 12 corneas. Notably, anterior chamber invasion occurred in saline and MOX groups but in none of the FDC-containing groups, and perforations were absent in all FDC and PT treatments. CONCLUSIONS: FDC + PT was superior to monotherapies and to FDC + MOX, achieving frequent sterilization and preventing intraocular spread and corneal perforations. These data support PT alone or in combination with FDC as promising therapeutic candidates for the treatment of XDR P. aeruginosa keratitis.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Romanowski EG, Young EK, Mandell JB, et al. Enhanced Efficacy of Cefiderocol With PolyTrim Combination Therapy in a Rabbit Model of Extensively Drug-Resistant Pseudomonas aeruginosa Keratitis. Invest Ophthalmol Vis Sci. 2026. PMID: 42153783. doi:10.1167/iovs.67.5.48

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。